Tenalisib
As of the edition of 20 October 2026, Tenalisib is a small molecule: in active development; acts on PIK3CD and PIK3CG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 11, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 7 | 5 | 1 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Rhizen Pharmaceuticals | Lead sponsor of trials | 2013 to now |